Effect of COMBO Endoscopy of Oropharyngeal Airways versus Conventional Nasal Cannula on Hypoxaemia in Obese Patients Undergoing Gastrointestinal Endoscopy under Sedation: A Randomised Controlled Trial
Year: 2026
Type: preprint
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Background Compared with the general patient population, obese patients are more susceptible to adverse events such as hypoxaemia and airway obstruction during sedation. Furthermore, during gastrointestinal endoscopy, presence of the endoscope in the airway complicates airway management. This not only poses significant challenges for anaesthesiologists but also directly threatens patient safety. Currently, simple yet effective airway management tools specifically designed for gastroscopy in clinical practice are lacking. This study aimed to evaluate whether the use of Capnography Monitoring Bite Block Oxygenation (COMBO) endoscopy of the oropharyngeal airway could reduce the incidence of hypoxaemia and other respiratory-related adverse events compared to that with traditional nasal cannula oxygen therapy in obese patients undergoing gastrointestinal endoscopy under sedation. Methods This single-centre, prospective, randomised, single-blinded trial (1:1) included 226 adult patients with a BMI of 30–40 kg·m⁻² and an ASA physical status of I–II who were scheduled for gastrointestinal endoscopy under deep sedation with propofol–sufentanil. Participants were randomly assigned to receive either COMBO (M group) or a nasal sampling cannula (N group). Both groups received oxygen at 5–6 L·min⁻¹ with standard monitoring. The primary outcome was hypoxaemia (75% ≤ SpO₂ < 90% for ≤ 60 s). Secondary outcomes included severe hypoxaemia; airway interventions and intensity; respiratory and haemodynamic variables; anaesthetic use; procedure and recovery times; adverse events; and patient satisfaction. Results COMBO significantly reduced the incidence of hypoxaemia compared with nasal cannula (11.11% vs. 42.86%; RR, 0.26; 95% CI, 0.15–0.46; P < 0.001; NNTB, 3; 95% CI, 2–6). The airway intervention rate and intensity were also lower in the device group ( P = 0.002 and P < 0.001, respectively). Among groups M and N, group×time interactions were significant for IPI, RR, SpO₂, and PETCO₂ (all P group×time < 0.001), were borderline significant for MAP (P group = 0.044), and were nonsignificant for HR (P group×time = 0.178). Moreover, the main effects of group were significant for all the variables (all P group < 0.001). Conclusions In obese adults undergoing gastrointestinal endoscopy with sedation, the COMBO airway provides a favourable risk–benefit profile by effectively reducing the incidence of hypoxaemia and airway events and improving cardiorespiratory stability. Clinical trial registration number: NCT06590922
Source: Research Square
Institution: Shandong First Medical University
Language: English
Subfield: Anesthesiology and Pain Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225889663
